Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity

Abstract Background FOLFIRINOX has increased efficacy but also toxicity. Despite various modified FOLFIRINOX regimens, how much reduction is acceptable remains unclear. This study aimed to find the optimal relative dose intensity (RDI, %) of FOLFIRINOX that preserves tumour responses in patients wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2017-05, Vol.76, p.125-133
Hauptverfasser:	Lee, Jong-chan, Kim, Jin Won, Ahn, Soyeon, Kim, Hyoung Woo, Lee, Jongchan, Kim, Young Hoon, Paik, Kyu-hyun, Kim, Jaihwan, Hwang, Jin-Hyeok
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced pancreatic cancer Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cancer Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - pathology Chemotherapy-Induced Febrile Neutropenia - drug therapy Chemotherapy-Induced Febrile Neutropenia - etiology Colony-stimulating factor cRDI Disease control Dose-Response Relationship, Drug Female Fluorouracil - administration & dosage FOLFIRINOX Granulocyte colony-stimulating factor Granulocyte Colony-Stimulating Factor - therapeutic use Hematology, Oncology and Palliative Medicine Humans Leucovorin - administration & dosage Leukocytes (granulocytic) Male Metastases Middle Aged Neoplasm Metastasis Neutropenia Neutropenia - drug therapy Neutropenia - etiology Organoplatinum Compounds - administration & dosage Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Patients Prophylaxis Relative dose intensity Sensitivity Thresholds Toxicity Tumors Tumour response
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!